(Q40662077)

22 September 2017

The radiosensitising effect of gemcitabine and the influence of the rescue agent amifostine in vitro (English)

1 reference

22 September 2017

6

1 reference

22 September 2017

B Pauwels

1

1 reference

22 September 2017

A E C Korst

2

1 reference

22 September 2017

C M J de Pooter

3

1 reference

22 September 2017

H A J Lambrechts

4

1 reference

22 September 2017

G G O Pattyn

5

1 reference

22 September 2017

J B Vermorken

7

1 reference

22 September 2017

1 April 2003

1 reference

European Journal of Cancer

22 September 2017

1 reference

22 September 2017

39

1 reference

22 September 2017

6

1 reference

22 September 2017

838-846

1 reference

Maximizing therapeutic gain with gemcitabine and fractionated radiation

22 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

Gemcitabine and radiosensitization in human tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

The effect of 2'-2' difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

Can WR-2721 be improved upon?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

New colorimetric cytotoxicity assay for anticancer-drug screening

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

Optimization of the sulforhodamine B colorimetric assay

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900002-9

7 January 2021

10.1016/S0959-8049(03)00002-9

Identifiers

DOI

1 reference

release_zs3hnsktjnhtbbqzqubjbvqkqi

22 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zs3hnsktjnhtbbqzqubjbvqkqi

24 November 2022

mapped directly with Wikidata item

1 reference